In fit metastatic
colorectal cancer (MCRC), multidisciplinary treatment strategy integrating intensive FIr-B/FOx triplet
chemotherapy associated to
bevacizumab and secondary
metastasectomies significantly improved clinical outcomes up to progression-free survival (PFS) 17 months and overall survival (OS) 44 months. A non-elderly woman affected by
rectal cancer, lymph nodes involvement, synchronous unresectable liver
metastases, was treated with first-line FIr-B/FOx integrated with two-stage liver resections, short course
radiotherapy, anterior rectal resection, with a PFS 9 months and progression-free interval (PFI) 4 months off-treatment. After progression characterized by single liver and lymph node inferior mesenteric axis
metastases, FIr-B/FOx was re-introduced, liver and lymph node resections were performed, with a PFS 8 months and PFI 3 months. FIr-B/FOx was further proposed due to bilateral lung, and liver
metastases with stable disease, PFS 8 months. Patient experienced a limiting toxicity syndrome multiple sites (LTS-ms) with G3
diarrhea, G2
asthenia,
nausea, requiring
irinotecan reduction and
5-fluorouracil discontinuation, and subsequent
oxaliplatin discontinuation, due to infusional
hypersensitivity reaction. Overall, integrated first-line medical and surgical treatment strategies gained PFS 26 months. Further lines II-V of treatment obtained a combined PFS 28 months: modulated
aflibercept/
irinotecan, PFS 8 months;
panitumumab, PFS 8 months, proposed due to KRAS/NRAS/BRAF wild-type and EGFR c.2156 G>C (p.G719A) mutation, achieving
biomarkers reduction, lung, liver, lymph nodes partial responses;
regorafenib, PFS 8 months;
trifluridine-tipiracil, PFS 4 months and induced an LTS-ms, with febrile G4 leucopenia, G3
neutropenia,
thrombocytopenia,
asthenia, G2
anemia,
diarrhea,
hypotension. After 2 months of
palliative care, patient died, at OS 58 months, gained by intensive medical/surgical treatments coupled with patient's resilience. To date, selection of tailored medical treatments, according to clinical (age, performance and comorbidity status) and molecular (RAS/BRAF and pharmacogenomic analyses) evaluations, careful monitoring of individual toxicity syndromes, potential integration of
metastasectomies, and furthermore individual resilience as patient life priority need to challenge MCRC long-term survival.